

**List of contents**

<b>CHAPTER 1 Introduction</b>	<b>1</b>
1.1 Insights into cancer disease	1
1.2 Protein tyrosine kinases	3
1.2.1 Classification of protein tyrosine kinases	4
1.2.2 Protein tyrosine kinases as targets in cancer therapy	6
1.3 Tyrosine kinase inhibitors (TKIs)	7
1.3.1 Classification of TKIs	8
1.3.2 Side effects of TKIs	11
1.3.3 Skin anatomy	14
1.4 Drug-induced photosensitivity	19
1.4.1 Mechanisms of drug-induced photosensitivity	23
1.4.2 Sunlight-mediated damage to biomolecules	27
1.5 DNA damage repair	33
1.6 Cell death	37
1.7 Molecular photochemistry	40
1.7.1 Photophysical processes	41
1.7.2 Photochemical processes	47
1.7.3 Singlet oxygen	48
1.8 Background on TKIs photobehavior	51
1.8.1 Phototoxicity prediction based on chemical structure	51
1.8.2 Photodynamic therapy	54
<b>CHAPTER 2 Aims and Objectives</b>	<b>57</b>
2.1 Significance of the study	59
2.2 Objectives	60
<b>CHAPTER 3 Materials and Methods</b>	<b>63</b>
3.1 Chemicals and reagents	65
3.2 Experimental procedures	66

3.2.1 Spectrophotometric techniques	66
3.2.2 Irradiation equipment	71
3.2.3 Cell culture conditions	72
3.2.4 Microscopic techniques	72
3.2.5 Phototoxicity	76
3.2.6 Lipid photoperoxidation	81
3.2.7 Protein photooxidation	84
3.2.8 Photogenotoxicity	85
3.2.9 Cell death	88
<b>CHAPTER 4 Screening of TKIs</b>	<b>91</b>
4.1 Tyrosine kinase inhibitors (TKIs) selection criteria	93
4.1.1 Absorption of UVA light	93
4.1.2 Neutral red uptake (NRU) phototoxicity test	95
4.2 Photostability of TKIs	99
<b>CHAPTER 5 Gefitinib</b>	<b>101</b>
5.1 Introduction	103
5.2 Experimental procedures	107
5.2.1 Neutral Red Uptake (NRU) phototoxicity test	107
5.2.2 Drug and metabolites cellular colocalization	107
5.2.3 Photosensitized lipid peroxidation	107
5.2.4 Photoinduced protein oxidation assay	108
5.2.5 Single cell gel electrophoresis comet assay	108
5.2.6 Cell death assays	108
5.3 Results and discussion	109
5.3.1 Phototoxicity of gefitinib metabolites	109
5.3.2 Fluorescence	111
5.3.3 Lipid photoperoxidation	114
5.3.4 Protein photooxidation	116

5.3.5 Photogenotoxicity _____	118
5.3.6 Cell death _____	120
5.4 Conclusions _____	123
<b>CHAPTER 6 Axitinib _____</b>	<b>125</b>
6.1 Introduction _____	127
6.2 Experimental procedures _____	129
6.2.1 Neutral red uptake (NRU) phototoxicity test _____	130
6.2.2 Photoinduced protein oxidation assay _____	130
6.2.3 Single cell gel electrophoresis comet assay _____	130
6.2.4 Photoinduced phosphorylation of $\gamma$ -H2AX _____	130
6.3 Results and discussion _____	131
6.3.1 Photophysical properties _____	131
6.3.2 Phototoxicity of axitinib isomers _____	135
6.3.3 Photogenotoxicity _____	139
6.4 Conclusions _____	144
<b>CHAPTER 7 Dasatinib _____</b>	<b>147</b>
7.1 Introduction _____	149
7.2 Experimental procedures _____	151
7.2.1 Spectroscopic measurements _____	151
7.2.2 Phototoxicity assay in reconstructed human epidermis _____	152
7.2.3 Photosensitized lipid peroxidation _____	152
7.2.4 Photoinduced protein oxidation assay _____	152
7.2.5 Single cell gel electrophoresis comet assay _____	153
7.2.6 Photoinduced phosphorylation of $\gamma$ -H2AX _____	153
7.3 Results and discussion _____	153
7.3.1 Photophysical properties _____	153
7.3.2 Photosensitized damage to lipids and proteins _____	161
7.3.3 Photogenotoxicity _____	165

7.3.4 Phototoxicity in reconstructed human epidermis _____	169
7.4 Conclusions _____	172
<b>CHAPTER 8 Avapritinib _____</b>	<b>175</b>
8.1 Introduction _____	177
8.2 Experimental procedures _____	178
8.2.1 Photoinduced protein oxidation assay _____	179
8.2.2 Single cell gel electrophoresis (comet) assay _____	179
8.3 Results and discussion _____	179
8.3.1 Fluorescence _____	179
8.3.2 Protein photooxidation _____	180
8.3.3 Photogenotoxicity _____	181
8.4 Conclusions _____	183
<b>CHAPTER 9 Conclusions _____</b>	<b>185</b>
<b>REFERENCES _____</b>	<b>193</b>
<b>SCIENTIFIC CONTRIBUTIONS _____</b>	<b>219</b>

## List of figures

<b>Figure 1</b>   Global cancer burden in 2020. _____	2
<b>Figure 2</b>   Cancer therapy current approaches. _____	3
<b>Figure 3</b>   Protein tyrosine kinase (PTKs). _____	5
<b>Figure 4</b>   Receptor tyrosine kinases (RTKs). _____	7
<b>Figure 5</b>   Trends in tyrosine kinase inhibitors (TKIs) discovery. _____	10
<b>Figure 6</b>   Keratinocytes and fibroblast cells. _____	18
<b>Figure 7</b>   Ultraviolet (UV) spectrum-dependent skin penetration. _____	21
<b>Figure 8</b>   Photoinduced DNA damage. _____	35
<b>Figure 9</b>   Histone H2AX in DNA damage repair. _____	37
<b>Figure 10</b>   Necrosis vs Apoptosis. _____	39

<b>Figure 11</b>   Jablonski diagram. _____	42
<b>Figure 12</b>   Photochemical reactions. _____	48
<b>Figure 13</b>   Type II photodynamic reaction. _____	49
<b>Figure 14</b>   Molecular orbital diagrams. _____	49
<b>Figure 15</b>   Chemical structures of photoreactive TKIs. _____	52
<b>Figure 16</b>   Absorption spectrophotometry. _____	66
<b>Figure 17</b>   Fluorescence spectrophotometry. _____	67
<b>Figure 18</b>   Laser flash photolysis (LFP). _____	70
<b>Figure 19</b>   Expansion microscopy. _____	76
<b>Figure 20</b>   Lipid peroxidation assay probe C11-Bodipy. _____	83
<b>Figure 21</b>   Normalized absorption spectra of TKIs. _____	95
<b>Figure 22</b>   Neutral red uptake (NRU) assay of TKIs. _____	98
<b>Figure 23</b>   Photostability of TKIs. _____	100
<b>Figure 24</b>   Gefitinib (GFT) and its metabolites. _____	105
<b>Figure 25</b>   NRU dose-response curves for GFT and metabolites. _____	110
<b>Figure 26</b>   Emission spectra of GFT and metabolites. _____	112
<b>Figure 27</b>   Relative fluorescence emission of GFT and metabolites. _____	113
<b>Figure 28</b>   Intracellular colocalization of of GFT and metabolites. _____	114
<b>Figure 29</b>   TBARS assay for GFT and metabolites. _____	115
<b>Figure 30</b>   Lipid peroxidation quenching experiment. _____	116
<b>Figure 31</b>   Protein photooxidation by GFT and metabolites. _____	117
<b>Figure 32</b>   Photogenotoxicity by GFT and metabolites. _____	119
<b>Figure 33</b>   Apoptosis vs necrosis. _____	122
<b>Figure 34</b>   Photoisomerization of axitinib (AXT). _____	128
<b>Figure 35</b>   Absorption spectra of AXT. _____	131
<b>Figure 36</b>   Photostability of ( <i>E</i> )-AXT upon UVA radiation. _____	133
<b>Figure 37</b>   Photostability of ( <i>Z</i> )-AXT upon UVA radiation. _____	134
<b>Figure 38</b>   NRU dose-response curves for AXT. _____	137

<b>Figure 39</b>   Protein photooxidation by AXT. _____	138
<b>Figure 40</b>   Alkaline comet assay experiment for AXT. _____	139
<b>Figure 41</b>   Expansion microscopy. _____	140
<b>Figure 42</b>   H2AX histone detection by expansion microscopy. _____	142
<b>Figure 43</b>   Immunofluorescence staining of $\gamma$ -H2AX. _____	143
<b>Figure 44</b>   Chemical structure of dasatinib (DAS). _____	149
<b>Figure 45</b>   Fluorescence properties of DAS. _____	155
<b>Figure 46</b>   Laser flash photolysis measurements. _____	156
<b>Figure 47</b>   Triplet-triplet energy transfer. _____	157
<b>Figure 48</b>   Singlet oxygen measurements. _____	159
<b>Figure 49</b>   Quenching of $^3\text{DAS}^*$ by biomolecules. _____	161
<b>Figure 50</b>   Photosensitized lipid peroxidation by DAS. _____	164
<b>Figure 51</b>   Photooxidation of HSA protein by DAS. _____	165
<b>Figure 52</b>   Alkaline comet assay experiment for DAS. _____	166
<b>Figure 53</b>   Immunofluorescence staining of $\gamma$ -H2AX for DAS. _____	168
<b>Figure 54</b>   Phototoxicity of DAS in the reconstructed epidermis. _____	170
<b>Figure 55</b>   Histological analysis. _____	171
<b>Figure 56</b>   Chemical structure of avapritinib (AVP). _____	177
<b>Figure 57</b>   Fluorescence emission properties of AVP. _____	180
<b>Figure 58</b>   Photooxidation of HSA protein by AVP. _____	181
<b>Figure 59</b>   Photogenotoxicity of AVP. _____	182

## List of tables

<b>Table 1</b>   Documentation on FDA-Approved tyrosine kinase inhibitors. ____	9
<b>Table 2</b>   Classification of adverse effects of TKI therapy. _____	12
<b>Table 3</b>   Photosensitizing FDA reported drugs. _____	22
<b>Table 4</b>   Main differences between phototoxicity and photoallergy. _____	27
<b>Table 5</b>   Guideline for Type I/Type II oxidation mechanisms. _____	30

<b>Table 6</b>   Values of phototoxic potential (PIF) by NRU assay. _____	99
<b>Table 7</b>   GFT and metabolites concentration for cell death assays. ____	108
<b>Table 8</b>   HaCaT NRU assay of GFT and its metabolites. _____	110
<b>Table 9</b>   Emission maximum wavelength of GFT and metabolites. ____	112
<b>Table 10</b>   HaCaT NRU phototoxicity of AXT isomers. _____	137
<b>Table 11</b>   Expansion microscopy. _____	141
<b>Table 12</b>   Photophysical parameters of DAS in different media. _____	160

### List of equations

<b>Equation 1</b>   Beer-Lamber law. _____	44
<b>Equation 2</b>   Planck equation. _____	68
<b>Equation 3</b>   Fluorescence quantum yield. _____	68
<b>Equation 4</b>   Stern-Volmer. _____	70
<b>Equation 5</b>   Singlet oxygen quantum yield. _____	71
<b>Equation 6</b>   UVA irradiation dose. _____	72
<b>Equation 7</b>   Photoirritant factor (PIF). _____	78
<b>Equation 8</b>   Quantification of lipid peroxidation. _____	84
<b>Equation 9</b>   Quantification of carbonyl content. _____	85
<b>Equation 10</b>   Quantification of DNA damage by comet assay. _____	87
<b>Equation 11</b>   Quantification of LDH activity. _____	91
<b>Equation 12</b>   Stern Volmer for singlet oxygen quenching by DAS. ____	152